Patients treated with widely used osteoporosis drugs may develop severe and sometimes disabling pain in muscles, joints and bones, U.S. officials said on Monday in an alert highlighting the previously known risk. The warning applies to Merck & Co Inc’s Fosamax, Roche Holding AG and GlaxoSmithKline PLC’s Boniva, plus all other members of the family known as bisphosphonates.
